infarction
Accordingly, tissue-type       plasminogen activator (t-PA) is frequently administered to patients with       recurrent infarction presenting more than four days from previous treatment with        streptokinase.
Accordingly, tissue-type       plasminogen activator (t-PA) is frequently administered to  @OBJECT$   @PREDICAT$        recurrent  @SUBJECT$  presenting more than four days from previous treatment with        streptokinase.